+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nanoemulsions - Global Market Trajectory & Analytics

  • ID: 5140632
  • Report
  • April 2021
  • Region: Global
  • 153 Pages
  • Global Industry Analysts, Inc
Global Nanoemulsions Market to Reach $14.4 Billion by 2027

Amid the COVID-19 crisis, the global market for Nanoemulsions estimated at US$8.5 Billion in the year 2020, is projected to reach a revised size of US$14.4 Billion by 2027, growing at a CAGR of 7.8% over the analysis period 2020-2027. Topical, one of the segments analyzed in the report, is projected to record a 7.4% CAGR and reach US$3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Oral segment is readjusted to a revised 8% CAGR for the next 7-year period.



The U.S. Market is Estimated at $2.5 Billion, While China is Forecast to Grow at 7.3% CAGR

The Nanoemulsions market in the U.S. is estimated at US$2.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2027 trailing a CAGR of 7.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.2% and 6.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.4% CAGR.

Parenteral Segment to Record 8.9% CAGR

In the global Parenteral segment, USA, Canada, Japan, China and Europe will drive the 9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$2.1 Billion in the year 2020 will reach a projected size of US$3.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.7 Billion by the year 2027.

Select Competitors (Total 43 Featured):
  • AbbVie, Inc.
  • Allergan PLC
  • AstraZeneca PLC
  • Covaris, Inc.
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Kaken Pharmaceutical Co., Ltd.
  • NanoBio Corporation
  • Novartis International AG
  • Sanofi SA
Frequently Asked Questions about the Global Market for Nanoemulsions

What is the estimated value of the Global Market for Nanoemulsions?

The Global Market for Nanoemulsions was estimated to be valued at $8.5 Billion in 2020.

What is the growth rate of the Global Market for Nanoemulsions?

The growth rate of the Global Market for Nanoemulsions is 7.8%, with an estimated value of $14.4 Billion by 2027.

What is the forecasted size of the Global Market for Nanoemulsions?

The Global Market for Nanoemulsions is estimated to be worth $14.4 Billion by 2027.
Note: Product cover images may vary from those shown

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Nanoemulsions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World 7-Year Perspective for Nanoemulsions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
  • Table 3: World Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 4: World 7-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 5: World Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 6: World 7-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 7: World Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World 7-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 9: World Current & Future Analysis for Nasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 10: World 7-Year Perspective for Nasal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 11: World Current & Future Analysis for Steroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 12: World 7-Year Perspective for Steroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 13: World Current & Future Analysis for Anesthetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World 7-Year Perspective for Anesthetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 15: World Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 16: World 7-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 17: World Current & Future Analysis for Immunosuppressant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 18: World 7-Year Perspective for Immunosuppressant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 19: World Current & Future Analysis for Antiretroviral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 20: World 7-Year Perspective for Antiretroviral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 21: World Current & Future Analysis for Antimicrobials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 22: World 7-Year Perspective for Antimicrobials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 23: World Current & Future Analysis for Vasodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 24: World 7-Year Perspective for Vasodilators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS
  • UNITED STATES
  • Table 25: USA Current & Future Analysis for Nanoemulsions by Route Of Administration - Topical, Oral, Parenteral and Nasal - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 26: USA 7-Year Perspective for Nanoemulsions by Route Of Administration - Percentage Breakdown of Value Sales for Topical, Oral, Parenteral and Nasal for the Years 2020 & 2027
  • Table 27: USA Current & Future Analysis for Nanoemulsions by Application - Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 28: USA 7-Year Perspective for Nanoemulsions by Application - Percentage Breakdown of Value Sales for Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators for the Years 2020 & 2027
  • CANADA
  • Table 29: Canada Current & Future Analysis for Nanoemulsions by Route Of Administration - Topical, Oral, Parenteral and Nasal - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 30: Canada 7-Year Perspective for Nanoemulsions by Route Of Administration - Percentage Breakdown of Value Sales for Topical, Oral, Parenteral and Nasal for the Years 2020 & 2027
  • Table 31: Canada Current & Future Analysis for Nanoemulsions by Application - Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 32: Canada 7-Year Perspective for Nanoemulsions by Application - Percentage Breakdown of Value Sales for Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators for the Years 2020 & 2027
  • JAPAN
  • Table 33: Japan Current & Future Analysis for Nanoemulsions by Route Of Administration - Topical, Oral, Parenteral and Nasal - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 34: Japan 7-Year Perspective for Nanoemulsions by Route Of Administration - Percentage Breakdown of Value Sales for Topical, Oral, Parenteral and Nasal for the Years 2020 & 2027
  • Table 35: Japan Current & Future Analysis for Nanoemulsions by Application - Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 36: Japan 7-Year Perspective for Nanoemulsions by Application - Percentage Breakdown of Value Sales for Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators for the Years 2020 & 2027
  • CHINA
  • Table 37: China Current & Future Analysis for Nanoemulsions by Route Of Administration - Topical, Oral, Parenteral and Nasal - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: China 7-Year Perspective for Nanoemulsions by Route Of Administration - Percentage Breakdown of Value Sales for Topical, Oral, Parenteral and Nasal for the Years 2020 & 2027
  • Table 39: China Current & Future Analysis for Nanoemulsions by Application - Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 40: China 7-Year Perspective for Nanoemulsions by Application - Percentage Breakdown of Value Sales for Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators for the Years 2020 & 2027
  • EUROPE
  • Table 41: Europe Current & Future Analysis for Nanoemulsions by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 42: Europe 7-Year Perspective for Nanoemulsions by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
  • Table 43: Europe Current & Future Analysis for Nanoemulsions by Route Of Administration - Topical, Oral, Parenteral and Nasal - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: Europe 7-Year Perspective for Nanoemulsions by Route Of Administration - Percentage Breakdown of Value Sales for Topical, Oral, Parenteral and Nasal for the Years 2020 & 2027
  • Table 45: Europe Current & Future Analysis for Nanoemulsions by Application - Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 46: Europe 7-Year Perspective for Nanoemulsions by Application - Percentage Breakdown of Value Sales for Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators for the Years 2020 & 2027
  • FRANCE
  • Table 47: France Current & Future Analysis for Nanoemulsions by Route Of Administration - Topical, Oral, Parenteral and Nasal - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 48: France 7-Year Perspective for Nanoemulsions by Route Of Administration - Percentage Breakdown of Value Sales for Topical, Oral, Parenteral and Nasal for the Years 2020 & 2027
  • Table 49: France Current & Future Analysis for Nanoemulsions by Application - Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 50: France 7-Year Perspective for Nanoemulsions by Application - Percentage Breakdown of Value Sales for Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators for the Years 2020 & 2027
  • GERMANY
  • Table 51: Germany Current & Future Analysis for Nanoemulsions by Route Of Administration - Topical, Oral, Parenteral and Nasal - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 52: Germany 7-Year Perspective for Nanoemulsions by Route Of Administration - Percentage Breakdown of Value Sales for Topical, Oral, Parenteral and Nasal for the Years 2020 & 2027
  • Table 53: Germany Current & Future Analysis for Nanoemulsions by Application - Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 54: Germany 7-Year Perspective for Nanoemulsions by Application - Percentage Breakdown of Value Sales for Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators for the Years 2020 & 2027
  • ITALY
  • Table 55: Italy Current & Future Analysis for Nanoemulsions by Route Of Administration - Topical, Oral, Parenteral and Nasal - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 56: Italy 7-Year Perspective for Nanoemulsions by Route Of Administration - Percentage Breakdown of Value Sales for Topical, Oral, Parenteral and Nasal for the Years 2020 & 2027
  • Table 57: Italy Current & Future Analysis for Nanoemulsions by Application - Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 58: Italy 7-Year Perspective for Nanoemulsions by Application - Percentage Breakdown of Value Sales for Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators for the Years 2020 & 2027
  • UNITED KINGDOM
  • Table 59: UK Current & Future Analysis for Nanoemulsions by Route Of Administration - Topical, Oral, Parenteral and Nasal - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 60: UK 7-Year Perspective for Nanoemulsions by Route Of Administration - Percentage Breakdown of Value Sales for Topical, Oral, Parenteral and Nasal for the Years 2020 & 2027
  • Table 61: UK Current & Future Analysis for Nanoemulsions by Application - Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 62: UK 7-Year Perspective for Nanoemulsions by Application - Percentage Breakdown of Value Sales for Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators for the Years 2020 & 2027
  • REST OF EUROPE
  • Table 63: Rest of Europe Current & Future Analysis for Nanoemulsions by Route Of Administration - Topical, Oral, Parenteral and Nasal - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 64: Rest of Europe 7-Year Perspective for Nanoemulsions by Route Of Administration - Percentage Breakdown of Value Sales for Topical, Oral, Parenteral and Nasal for the Years 2020 & 2027
  • Table 65: Rest of Europe Current & Future Analysis for Nanoemulsions by Application - Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 66: Rest of Europe 7-Year Perspective for Nanoemulsions by Application - Percentage Breakdown of Value Sales for Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators for the Years 2020 & 2027
  • ASIA-PACIFIC
  • Table 67: Asia-Pacific Current & Future Analysis for Nanoemulsions by Route Of Administration - Topical, Oral, Parenteral and Nasal - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 68: Asia-Pacific 7-Year Perspective for Nanoemulsions by Route Of Administration - Percentage Breakdown of Value Sales for Topical, Oral, Parenteral and Nasal for the Years 2020 & 2027
  • Table 69: Asia-Pacific Current & Future Analysis for Nanoemulsions by Application - Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 70: Asia-Pacific 7-Year Perspective for Nanoemulsions by Application - Percentage Breakdown of Value Sales for Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators for the Years 2020 & 2027
  • REST OF WORLD
  • Table 71: Rest of World Current & Future Analysis for Nanoemulsions by Route Of Administration - Topical, Oral, Parenteral and Nasal - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 72: Rest of World 7-Year Perspective for Nanoemulsions by Route Of Administration - Percentage Breakdown of Value Sales for Topical, Oral, Parenteral and Nasal for the Years 2020 & 2027
  • Table 73: Rest of World Current & Future Analysis for Nanoemulsions by Application - Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 74: Rest of World 7-Year Perspective for Nanoemulsions by Application - Percentage Breakdown of Value Sales for Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials and Vasodilators for the Years 2020 & 2027

IV. COMPETITION
  • Total Companies Profiled: 43


Note: Product cover images may vary from those shown